Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marinus Charts The Way Forward For Ganaxolone Amid Business Challenges

Executive Summary

Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.

You may also be interested in...



Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

Marinus Finds Silver Lining In Ganaxolone Trial Miss

The biotech announces another poor performance for its lead drug candidate, but puts a positive spin on the data and plans continued development.

Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base

Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel